Loss of Heterozygosity of FCY2 Leading to the Development of Flucytosine Resistance in Candida tropicalis

ABSTRACT As fluconazole resistance becomes an emerging issue for treating infections caused by Candida tropicalis, searching for alternative becomes a prominent task. In the present study, 97 clinical isolates of C. tropicalis were tested for the susceptibilities to flucytosine (5FC) with the Etest method. Although only one isolate was resistant to 5FC, 30 susceptible isolates could produce resistant progeny after exposure to the drug. Interestingly, 22 of these 30 clinical isolates had a heterozygous G/T at the 145th position on FCY2, encoding purine-cytosine permease, whereas their progeny recovered from within the inhibitory ellipses had homozygous T/T, resulting in null alleles for both copies of the gene and produced only truncated proteins, effecting the 5FC resistance. Furthermore, we found that two major fluconazole-resistant clinical clones, diploid sequence type 98 (DST98) and DST140, had a homozygous G/G at the 145th position, and neither was able to produce 5FC-resistant progeny within the inhibitory ellipses. Hence, strains of C. tropicalis containing heterozygous alleles may develop 5FC resistance readily, whereas those with homozygous G/G wild-type alleles can be treated with 5FC. Subsequently, a combination of 5FC and another antifungal drug is applicable for treating infections of C. tropicalis.

[1]  W. Ko,et al.  Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999–2006 , 2011, Mycoses.

[2]  M. Falagas,et al.  Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  S. Katiyar,et al.  Mutational Analysis of Flucytosine Resistance in Candida glabrata , 2010, Antimicrobial Agents and Chemotherapy.

[4]  A. Hasegawa,et al.  Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. , 2010, The Journal of antimicrobial chemotherapy.

[5]  B. Dujon,et al.  Population Polymorphism of Nuclear Mitochondrial DNA Insertions Reveals Widespread Diploidy Associated with Loss of Heterozygosity in Debaryomyces hansenii , 2010, Eukaryotic Cell.

[6]  A. Wang,et al.  The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. , 2010, Medical mycology.

[7]  Yu-Hsin Lin,et al.  The molecular epidemiology of serial Candida tropicalis isolates from ICU patients as revealed by multilocus sequence typing and pulsed-field gel electrophoresis. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[8]  B. Da Silva,et al.  Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae , 2009, Antimicrobial Agents and Chemotherapy.

[9]  P. D. Rogers,et al.  Mutations in the multi‐drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole‐resistant Candida albicans strains , 2008, Molecular microbiology.

[10]  D. Gottschling,et al.  A Genetic Screen for Increased Loss of Heterozygosity in Saccharomyces cerevisiae , 2008, Genetics.

[11]  Yun-Liang Yang,et al.  Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. , 2008, Diagnostic microbiology and infectious disease.

[12]  D. Shaw,et al.  Molecular phylogenetic analysis of Candida tropicalis isolates by multi-locus sequence typing. , 2008, Fungal genetics and biology : FG & B.

[13]  F. Dromer,et al.  Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France , 2008, Emerging infectious diseases.

[14]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[15]  H. Lo,et al.  Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. , 2007, Diagnostic microbiology and infectious disease.

[16]  P. Tambyah,et al.  Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. , 2007, Medical mycology.

[17]  N. Jain,et al.  Epidemiology of Candidemia in a Tertiary Care Centre of North India: 5-Year Study , 2007, Infection.

[18]  Yun-Liang Yang,et al.  Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. , 2007, Journal of medical microbiology.

[19]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[20]  Hsi-Tsung Cheng,et al.  Solution structure of a novel D-naphthylalanine substituted peptide with potential antibacterial and antifungal activities. , 2007, Biopolymers.

[21]  D. Warnock.  Trends in the epidemiology of invasive fungal infections. , 2007, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.

[22]  J. Villard,et al.  Molecular Mechanism of Flucytosine Resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 Genes to 5-Fluorouracil and Fluconazole Cross-Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[23]  J. Berman,et al.  A Mutation in Tac1p, a Transcription Factor Regulating CDR1 and CDR2, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in Candida albicans , 2006, Genetics.

[24]  J. Villard,et al.  Inactivation of the FCY2 Gene Encoding Purine-Cytosine Permease Promotes Cross-Resistance to Flucytosine and Fluconazole in Candida lusitaniae , 2005, Antimicrobial Agents and Chemotherapy.

[25]  Yun-Liang Yang,et al.  Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. , 2005, Diagnostic microbiology and infectious disease.

[26]  P. T. Magee,et al.  Demonstration of Loss of Heterozygosity by Single-Nucleotide Polymorphism Microarray Analysis and Alterations in Strain Morphology in Candida albicans Strains during Infection , 2005, Eukaryotic Cell.

[27]  D. Sanglard,et al.  TAC1, Transcriptional Activator of CDR Genes, Is a New Transcription Factor Involved in the Regulation of Candida albicans ABC Transporters CDR1 and CDR2 , 2004, Eukaryotic Cell.

[28]  L. Tabernero,et al.  Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.

[29]  R. Kolter,et al.  The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. , 2004, Gene.

[30]  D. Soll,et al.  Clade-Specific Flucytosine Resistance Is Due to a Single Nucleotide Change in the FUR1 Gene of Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.

[31]  Yun-Liang Yang,et al.  Susceptibilities of Candida Species to Amphotericin B and Fluconazole: The Emergence of Fluconazole Resistance in Candida tropicalis , 2004, Infection Control & Hospital Epidemiology.

[32]  Yun-Liang Yang,et al.  Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. , 2003, Diagnostic microbiology and infectious disease.

[33]  Yun-Liang Yang,et al.  Mechanisms of antifungal agent resistance. , 2001, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[34]  H. Guchelaar,et al.  Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. , 2000, The Journal of antimicrobial chemotherapy.

[35]  D. Sanglard,et al.  Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750 , 2000, Antimicrobial Agents and Chemotherapy.

[36]  L. Cowen,et al.  Evolution of Drug Resistance in Experimental Populations of Candida albicans , 2000, Journal of bacteriology.

[37]  Ronald N. Jones,et al.  Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.

[38]  D. Kelly,et al.  Multiple Molecular Mechanisms Contribute to a Stepwise Development of Fluconazole Resistance in Clinical Candida albicans Strains , 1998, Antimicrobial Agents and Chemotherapy.

[39]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[40]  T. C. White,et al.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[41]  S. Filler,et al.  Reversible fluconazole resistance in Candida albicans: a potential in vitro model , 1997, Antimicrobial agents and chemotherapy.

[42]  F. Sherman.  Getting started with yeast. , 1991, Methods in enzymology.

[43]  A. Polak,et al.  Mechanisms of action of 5-fluorocytosine , 1983, Antimicrobial Agents and Chemotherapy.

[44]  J. E. Bennett,et al.  Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.

[45]  A. Polak,et al.  Mode of action of 5-fluorocytosine and mechanisms of resistance. , 1975, Chemotherapy.